ICER Boosts ‘Cost-Recovery’ Benchmark Price For Remdesivir To Reflect Gilead’s Planned R&D

 
• By Cathy Kelly
  
Coronavirus dollar bill
Price Modeling A Challenge In Rapidly Changing Environment
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Market Access

More from Pink Sheet